Please wait
Merck & Co., Inc. (MRK) is listed on the Nigerian Exchange in the Healthcare sector, with exposure to Drug Manufacturers - General. This page brings together the current share price, valuation, dividend context, business summary, and a practical current view so you can assess the stock faster.
Healthcare
₦473T
2.7%
35.08
Current price
₦192,990.00
Updated Updated just now
Conviction
77/100
Confidence
Low
Market tone
neutral · 77/100
Entry
Medium · 77/100
Recent price action for MRK, so the page starts with the stock itself before the deeper analysis.
This is a reasonably large name with enough regular flow that normal-sized exits should usually be workable.
Valuation view
Looks relatively cheap vs peers
Income view
Low income profile
Market tone
neutral (77/100) — price action, attention, and recent context all lean here.
Entry view
Medium (77/100) — The company is profitable on the latest reported numbers.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca’s Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
Investors usually follow MRK for its dividend profile, valuation signal, sector position, and upcoming company events. The goal here is not just to show numbers, but to explain what they mean in plain English.
0
Dividend and company notices.
Market events
0
Insider, filing, dividend, and price events.
Source records
1
Captured updates we can trace.
Whisone is bullish because fundamentals are solid at 77/100 while there is no strong bear warning from the current data. Whisone has high conviction here. The final read is being balanced by the weighted scores for fundamentals, technicals, insider flow, sentiment, event flow, and liquidity.
Whisone v2 splits the read into weighted parts so the score is not just one hidden number.
Fundamentals
Growth, margins, cash flow, and valuation.
ROE
18.9%
Return on equity
ROA
12.6%
Return on assets
Debt / equity
1.07
Lower is usually safer.
P/B ratio
18.58
Useful for book value support.
Dividend yield
2.7%
Current income signal.
99/100
Direction
Positive bias
Main supports
Business quality and balance-sheet strength are supporting the outlook.
Valuation still leaves room versus fair value and analyst anchors.
Recent price behavior and momentum still support follow-through.
What can go wrong
Execution risk and market swings can still delay the forecast playing out.
Fair value
₦334,890.00
Analyst view
Buy
Analyst target
₦195,585.00
Forecast refresh
Updated just now
Quality score
75
Growth score
68.46
These are the external analyst numbers and business outlook figures already synced into the company record.
Low target
₦99,600,000,000,000.02
High target
₦101,250,000,000,000.00
Revenue this year
₦100T
Revenue next year
₦105T
EPS this year
₦4,110.00
EPS next year
₦14,340.00
Dividend / share
₦3,900.00
Forward P/E
10.97
Latest market date
2026-06-26
Dividend yield
2.7%
Ex-dividend date
Jun 15, 2026
MRK
Merck & Co., Inc.
Price: ₦192,990.00
P/E: 35.08
Yield: 2.7%
ABBV
AbbVie Inc.
Price: ₦380,025.00
P/E: 124.8
Yield: 2.7%
ABT
Abbott Laboratories
Price: ₦141,180.00
P/E: 26.36
Yield: 2.7%
AMGN
Amgen Inc.
Price: ₦537,495.00
P/E: 24.94
Yield: 2.8%
Industry
Drug Manufacturers - General
Founded
2000
Employees
75,000
Exchange
NYSE
Ticker
MRK
